Acer up on China patent for genetic disorder treatment

Acer Therapeutics

08/07/2022 14:17

** Shares of Acer Therapeutics  ACER.O  rise 10.7% to $1.55
premarket
    ** Co says China National Intellectual Property
Administration has issued patent for experimental drug candidate
ACER-001 for treatment of patients with urea cycle disorders and
Maple Syrup Urine Disease
    ** In June, U.S. FDA declined to approve ACER-001 for
treatment of patients with urea cycle disorders, citing need to
inspect third-party contract packaging manufacturer  urn:newsml:reuters.com:*:nL4N2Y82R1
    ** Newly issued patent has expiration date of Aug 24, 2031
    ** Stock down ~38.6% YTD, as of last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com;))